| Delayed Nasdaq Stockholm Other stock markets | 5-day change | 1st Jan Change | ||
| 310.80 SEK | +0.13% |  | +0.13% | +16.40% |
| 12-12 | US FDA Accepts Sobi's Thrombocytopenia Drug Application | MT |
| 12-11 | Swedish Orphan Biovitrum AB Elects David Meek as Member of the Board of Directors and Chair of the Board of Directors | CI |
February 08, 2023 at 02:00 am
Share
Swedish Orphan Biovitrum AB (publ) provided earnings guidance for 2023. Revenue is anticipated to grow by a low-to-mid single-digit percentage at CER.
Share
© S&P Capital IQ - 2023
Latest news about Swedish Orphan Biovitrum AB
| US FDA Accepts Sobi's Thrombocytopenia Drug Application | 12-12 | MT |
| Swedish Orphan Biovitrum AB Elects David Meek as Member of the Board of Directors and Chair of the Board of Directors | 12-11 | CI |
| RBC lowers target price for Sobi to SEK 400 (410), reiterates outperform - BN | 12-10 | FW |
| Aktiespararna puts buy on Sobi, target price SEK 370 | 12-09 | FW |
| Sobi to present new data at ASH | 12-03 | FW |
| Di: These seven hard-to-get stocks to buy according to the experts | 11-29 | FW |
| Danske Bank Upgrades Sobi to Buy, Lifts PT | 11-25 | MT |
| Danske Bank raises Sobi to buy (keep), target price 340 SEK - BN | 11-25 | FW |
| HSBC raises target price for Sobi to SEK 390 (330), reiterates Buy - BN | 11-14 | FW |
| Global markets live: Palantir soars, Boeing strike ends | 11-05 |  |
| Stockholm Bullets - EQT makes bid for OEM with negative premium | 11-05 | FW |
| Sobi's Nomination Committee proposes Daniel Meek as new Chairman - calls for Extraordinary General Meeting | 11-05 | FW |
| Swedish Orphan Biovitrum Nominates New Chair | 11-04 | MT |
| Swedish Orphan Biovitrum AB Announces Annette Clancy Has Informed the Nomination Committee That Will Not Be Available for Re-Election as Chair | 11-04 | CI |
| RBC raises target price for Sobi to SEK 410 (370), reiterates outperform - BN | 11-01 | FW |
| Increased sales consensus on Sobi after report | 10-31 | FW |
| Sobi to present new emapalumab results next month | 10-30 | FW |
| Berenberg raises target price for Sobi to SEK 400 (325), reiterates Buy - BN | 10-29 | FW |
| SEB Bank Upgrades Sobi to Buy, Boosts PT | 10-28 | MT |
| SEB raises Sobi to buy (hold), target price SEK 400 - BN | 10-28 | FW |
| Jefferies raises target price for Sobi to SEK 310 (300), reiterates Hold | 10-28 | FW |
| Sobi and Apellis present Valiant study results at Kidney Week | 10-28 | FW |
| Pareto Securities raises target price for Sobi to SEK 385 (345), reiterates Buy | 10-28 | FW |
| Sobi and Apellis Pharmaceuticals, Inc. Announces Detailed Data from the Phase 3 Valiant Study | 10-27 | CI |
Chart Swedish Orphan Biovitrum AB
SOBI: Dynamic Chart
Company Profile
Swedish Orphan Biovitrum publ AB is a Sweden-based pharmaceutical company. The Company develops, manufactures and sells medications within hemophilia, autoimmune diseases, metabolic diseases and cancer supportive care. The Companyâs product portfolio is divided into three business segments: the Core Products segment offers pharmaceuticals within Inflammation area, and Genetics and metabolic therapeutic area; the Partner Products segment offers about 40 pharmaceuticals within hematology, oncology and emergency medicines, and the ReFacto Manufacturing segment. The Company has subsidiaries in Sweden, Denmark, Finland, Norway, United Kingdom and France, among others. On September 9, 2013, the Company acquired the full rights to develop and commercialize Kineret (anakinra) from Amgen, the biotechnology company based in the United States.
Employees
1,814
Sector
Pharmaceuticals
Calendar
2025-02-04 - Q4 2024 Earnings Release
More about the company
Income Statement and Estimates
More financial data
Ratings
Trading Rating
Investor Rating
ESG Refinitiv
A
More Ratings
Analysts' Consensus
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
11
Last Close Price
310.80SEK
Average target price
359.73SEK
Spread / Average Target
+15.74%
Consensus
Profit revisions
Estimate revisions
Quarterly revenue - Rate of surprise
Company calendar
- Stock Market
- Equities
- SOBI Stock
- News Swedish Orphan Biovitrum AB
- Swedish Orphan Biovitrum AB Provides Earnings Guidance for 2023
